ISPOR 7th HTA Roundtable [Latin America]
Wednesday, September 9, 2009
ISPOR 2nd Biannual Latin America Meeting
Sheraton Rio Hotel, Rio de Janeiro, Brazil

MEETING DISCUSSION SUMMARY:

INTRODUCTION
The mission of ISPOR is to advance the science of pharmacoeconomics/health economics and health outcomes research (clinical, economic, and patient reported), and to foster and develop the use of this science in health care decisions. ISPOR holds annual roundtables to provide a forum for health care stakeholders to discuss, debate, and share information on health technology issues, as well as bridge the gap between health care decision makers and outcomes researchers to optimize health care decisions. The focus of the 7th HTA Roundtable was to discuss HTA issues from the Latin America perspective.

PARTICIPANTS
The list of participants for the HTA Roundtable that took place in Rio de Janeiro is given in Appendix A (below).

DISCUSSION SUMMARY
• General Discussion:

At the 7th HTA Council Roundtable was held September 9, 2009, in Rio de Janeiro, Brazil, after the ISPOR 2nd Latin America Conference, participants introduced their role in HTA, and presented a brief description of their organization’s type, purpose, HTA-related activities, and who their audience is. They identified the need for training & formation of high level people and the need for transferability from one country to another. The following are key issues identified by the HTA Council Roundtable [Latin America] for discussion and recommended action.

• HTA Council Issue: Methods & Studies
• HTA Council Issue: Translating HTA Information Health Care Decision
• HTA Council Issue: Need for HTA Information

Recommendations Identified by HTA Council Roundtable participants

IV HTA Methods & Studies
Doing HTA? Shortage
Need for specialized people (when sent for training they end up staying)
Need training & formation of high level people
Multi-disciplinary groups
(In Brazil a lot was done in the last 5 years in HTA)
Project financing in different LA countries (40)
Cooperation with PAHO/WHO (Project: Drugs price database)
How to reach decision-makers
WHO is working with different countries to transfer clinical trials from countries to regional?
Transferability from one country to another
From developed to developing countries
Content specific
Models are not necessarily transferrable
Limitations
Information sharing
Harmonization
Equity in technology access (rural to cities)

VI Translating HTA information for or by Health Policymakers
Discussion about HTA results from the decision-makers’ point of view

Need for HTA Information
What can ISPOR do for this region?
Translation of publications ✓ (ISPOR Book of Terms & Code of Ethics in Portuguese; upcoming ISPOR Value in Health Special Issue in English, Portuguese and Spanish)
Invite people to present ✓ (ISPOR Latin America Conferences and Regional Chapter Speakers’ Bureau)
Publications: if ViH can do the peer-review in Spanish of Portuguese before translating into English ✓ (ISPOR Value in Health Special Issue: Pharmacoeconomics & Outcomes Research in Latin America)
Get regional people together and support local meetings ✓ (ISPOR Conferences & Regional Chapter meetings)
Education: distance learning in Portuguese and Spanish ✓ (First 3 modules in Spanish and Portuguese to be launched September 2011)
Dealing with decision-makers at the local level is not easy but make policy briefs (continue roundtables like this one)
Identify common issues ✓ (ISPOR Latin America Consortium Working Committees)
Help in fundraising (institutional support) ✓ (ISPOR Regional Consortium Special Fund)
ISPOR platform to share experience with different groups on How to improve ✓ (Consortium & Conferences)
Some sort of task force on Latin America on this council (commitment with clear goals on what to do and who will follow) ✓ (ISPOR Latin America Consortium Health Technology Assessment (HTA Agencies Committee)
ISPOR Connections or ViH in Spanish then translated to English (researchers don’t have a problem with English, but the people using this research have) ✓ (ISPOR Value in Health Special Issue: Pharmacoeconomics & Outcomes Research in Latin America)